practical result. The diseases which are left for study are all rare conditions, and therefore if we are to study the subject of inborn errors of metabolism, we must study rare conditions. However, the number of these rare inborn errors of metabolism which we recognize is rapidly growing. When Garrod first discussed the subject (1908) he was concerned with only five diseases. The number recognized since then has increased by leaps and bounds. There are probably some hundreds recognized at present (Stevenson 1961) ; they occur in every branch of medicine and the list will almost certainly continue to grow. This means that every physician must expect to encounter some of these rare conditions and no apology is required for studying the general principles which govern them. For example, in neurology we have Wilson's disease, periodic paralysis, porphyria and Hartnup syndrome in addition to the large group where mental retardation is a striking feature (phenylketonuria, galactosoemia and Tay-Sachs disease).
If a normal chain of chemical events in the body is represented by the sequence: A > B C > D in which A is a substance entering the body and D the final metabolic product excreted, then the inborn error of metabolism is represented by the corresponding sequence:
A -B C -\\-+ d E A single enzyme which normally converts substance C into substance D is ineffective so that a metabolic block is set up. Therefore D is produced in diminished quantities (d) and C accumulates at its site of production. Occasionally it is the lack of D which gives rise to the clinical picture, as in inherited non-endemic goitrous cretinism (Stanbury & McGirr 1957) when there is a failure of thyroxine synthesis and the entire clinical picture may be prevented by thyroxine administration (provided this is done from an early age). More often it is the accumulation of C which either directly or indirectly causes the clinical manifestations. This substance may accumulate in the urine alone if the metabolic block is restricted to the renal tubules as in cystinuria (Dent & Rose 1951) or renal glycosuria. More often, there is a metabolic block in intermediary metabolism and substance C accumulates either in the cells, as in Tay-Sachs disease, Nieman-Pick disease and glycogen storage disease, or in plasma and urine as in phenylketonuria. Sometimes the abnormal substance first observed is not C itself, but its precursor B, or even A Thus in galactosxmia there is a failure of conver-sion of galactose 1-phosphate to glucose 1-phosphate, but the substance first found in excess was not galactose 1-phosphate, but free galactose in the urine. Another possibility is that the observed substance is not on the normal metabolic pathway A to D, but an alternative metabolite of C, designated E in the scheme above. This occurs in phenylketonuria when phenylalanine is converted to phenylketone as an alternative to the usual conversion to tyrosine. Despite these possible complications the basic simplicity of the idea of the metabolic block remains. Garrod (1908) postulated that the single enzyme *defect of an inborn error of metabolism was due to a defect in a single gene and that this explained why the diseases he studied were transmitted in accordance with the mendelian laws ofinheritance. This led directly to the 'one gene, one enzyme' theory which is as simple a concept as that of the metabolic block itself. These twin theories still hold the field virtually unchallenged. Inborn errors of metabolism, like other inherited characteristics, may be transmitted by recessive or dominant genes which may be autosomal or sexlinked and have varying degrees of penetrance. Nowadays our ideas have matured to the point where we can say that if any disease is transmitted in one of these genetic ways then there must be an inborn error of metabolism responsible for that disease. This means that in, say, Huntington's chorea and the familial ataxias there are inborn -errors of metabolism awaiting demonstration. Unfortunately, however, this knowledge does not make the block easier to locate.
The 'one geneone enzyme' theory also implies an 'all-or-nothing' effect. This means that in the case of an inborn error of metabolism transmitted by a dominant gene the affected enzyme is either completely normal or completely abnormal. In the case of the transmission by a recessive gene there is the further possibility that the heterozygous carrier of the disease might have an intermediate enzymic state. This type of individual has been recognized for phenylketonuria (Hsia & Paine 1957) , galactosemia (Kirkman & Bynum 1959) and acatalasemia (Nishimura et al. 1959) .
In contrast with the basic simplicity of the underlying principles are the complexities of what we actually observe in most patients with inborn errors of metabolism. This is because the biochemical observations that we are usually able to make are not sufficiently basic to reveal the simplicity. We want to measure the specific enzyme. Occasionally, as in acatalasxemia (Takahara 1952) , this is possible and the all-or-nothing effect is readily apparent. In hypophosphatasia we can measure the plasma alkaline phosphatase readily but the all-or-nothing effect is masked because we are measuring the enzyme in the wrong place and mixed with other phosphatases not affected in the disease. Usually, however, we do not even attempt to measure the enzyme itself, but rather the biochemical changes that have been produced in the body by the abnormal enzyme. These effects may be subject to the environment so that the basic allor-nothing effect may be completely masked. Thus in phenylketonuria the basic defect is failure to convert phenylalanine to tyrosine (Jervis 1947) . While this defect is constant throughout life we usually recognize the disease by observing the levels of phenylalanine or phenylketone in plasma or urine. But levels can be affected by diet and even made normal, so that the biochemical effects observed are quite inconstant.
In the Hartnup syndrome of Baron et al. (1956) , in which the basic enzyme abnormality has not yet been traced, there is a constant excessive amino-aciduria which is present in all affected individuals. The plasma levels of the amino acids are low so that there must be a renal tubular leak of amino acids. Since this defect is so constant throughout life we must suppose that it is closely related to the basic enzyme abnormality. In contrast with the constant amino-aciduria there is an inconstantly increased urinary indican and indole acetic acid, the excretions varying from individual to individual and from day to day in an individual. The excretion of indole derivatives should therefore be less closelyrelated to the basic abnormality. Milne et al. (1960) have indeed shown that the indican and indole acetic acid arise from bacterial breakdown of tryptophan in the gut and that this is due to delayed intestinal absorption of tryptophan in the same way as there is reduced renal tubular absorption of tryptophan. Hartnup syndrome may be accompanied by a pellagra-like rash. Since nicotinic acid, the anti-pellagra vitamin, is made in part from tryptophan and since Milne et al. (1960) also showed that patients with Hartnup syndrome break down less tryptophan along this metabolic pathway than do normals, the cause of the 'pellagra' becomes apparent. These workers consider the basic abnormality to be one of tryptophan transport into cells, not only in the renal tubules and the gut, but also at sites of inter-mediary metabolism.
When we turn from the biochemical picture to the clinical picture, we are passing away from the basic defect and seeing the results of all the metabolic changes. The picture is correspondingly more confusing. Even in as simple an example as inherited goitre due to failure to convert inorganic to organic iodine, we find the surprising added feature of nerve deafness (Brain 1927) . In familial paralysis the clinical manifestations are episodic. In Hartnup syndrome the pellagra-like rash may only be seen provided that nutrition is poor and provided there is exposure to sunlight. The cerebellar ataxia is intermittent and made worse by intercurrent infection. Milne et al. (1960) have suggested that if a toxic weak acid circulating in the plasma leads to this ataxia, then in starvation when the urine is acid the renal clearance of this weak acid would be reduced and the plasma level would increase and thus cause the clinical exacerbation.
At times the clinical picture may vary so much from patient to patient that it would be difficult or impossible to realize that these different clinical pictures had a common defect without the aid of the key biochemical investigations. Thus in the inherited type of renal tubular acidosis some patients present with periodic paralysis from potassium depletion, others with osteomalacia, and yet others with renal calculi. At other times the converse may occur, misleading us into believing that similar clinical syndromes have a common letiology. This occurred in glycogen storage disease, which is now subdivided into three distinct entities, and in periodic paralysis which can be subdivided into that with renal tubular acidosis and that without, the latter being subdivided into three groups according to the level of plasma potassium in an attack.
The idea of the metabolic block has done for inborn errors of metabolism what the idea of the infective agents did for the infective diseases. It has provided a readily understandable basic theory which in turn has enabled us to make further progress. We still do not know exactly how, say, raised plasma phenylalanine causes mental retardation any more than we know exactly how Vibrio cholera causes diarrhoea. However, just as we know how the fluid loss from the diarrheea must be replaced, similarly we now know how to lower the plasma phenylalanine in phenylketonuria to prevent mental damage. Since the feetus with an enzyme defect is often protected from harm by its mother, the paediatrician may encounter the resulting metabolic disturbances at a very early stage, often before they give rise to anything more than a vague failure to thrive or some indeterminate vomiting. This privilege carries with it corresponding obligations, and it is this aspect of metabolic disturbances in relation to neurology that I wish to emphasize. Once the possibility of a metabolic disorder arises biochemical investigations must be undertaken so that the pxdiatrician may elaborate treatment, whether dietary, substitutional or chelating in nature, and prevent the development of irreversible symptoms, particularly neurological ones. Certainly by the time we need to call in neurologists we have failed, either through our own fault or through lack of knowledge on the subject. Because of the particular frailty and immaturity of the brain in its tremendous growth and development over the first year or two there is a liability to irreversible damage. To illustrate this theme I will refer to three conditions of particular interest to both paediatricians and neurologists.
Neonatal Hyperbilirubinaemia and Kernicterus
Bilirubin, derived from haemoglobin, is the end of a metabolic line, being excreted only via the liver. Sufficient hkmoglobin is released each day as a result of the normal wastage of red cells to produce between 5 and 10 mg of bilirubin per 100 ml of blood and accumulates at this rate unless removed. Bilirubin is fat-but not water-soluble and is consequently not excretable; it circulates in the plasma loosely bound to albumin, and when the level rises above that which the plasma can accommodate, the pigment appears in the skin and the fat, and in some neurones in the central nervous system. Bilirubin is a toxic substance and, as fast as it is formed, is removed by the liver cells by a process of conjugation with glucuronic acid to form bilirubin glucuronide. This reaction is effected with the help of the enzyme bilirubin glucuronyl transferase.
This enzyme is apparently not present during feetal life, and birth triggers off its development. This leads to a temporary rise in plasma bilirubin even in normal infants during the first two or three days of life which is sometimes sufficient to give rise to the so-called physiological jaundice. In certain circumstances, however, as for example, in prematurity, the development of the enzyme is delayed, so that the rise in bilirubin continues inamia longer and much higher levels are reached. If the rise is sufficiently high toxic symptoms may develop in the central nervous system (Fig 1) . Schmorl (1904) observed that the bodies of jaundiced infants usually turned deep green when kept in formalin, but that a few retained a goldenyellow appearance. In the latter he often found bile-staining of certain groups of cells in the brain, but never in those that turned green. He called the condition kernicterus and thought there must be similar but different pigments responsible for jaundice. Later Guthrie (1914) described the clinical picture. The infant ceases to suck, looks ill, develops writhing movements and irregularities of respiration, finally lapses into coma, and often dies from respiratory failure. In some less severely affected cases the infant slowly improves but is left permanently damaged and develops as a mentally retarded athetoid child.
Without doubt, bilirubin itself is responsible for these symptoms. The oxygen consumption of chopped brain is greatly reduced (Lathe 1954 ) and phosphorylation in liver mitochondria is 'uncoupled', bringing metabolic activity to an end, when the concentration of bilirubin is similar to that at which it may be clinically toxic to infants, namely about 20 mg/100 ml (Zetterstrom & Ernster 1956 ). Not all regions of the brain are equally affected (Fig 2) . The sites of predilection include the thalamus, corpus striatum with the putamen and globus pallidus, the subthalamic nuclei, the nuclei of the III nerve, those round the floor of the fourth ventricle including the respiratory centre, the hippocampus, the olives and the dentate nucleus, and even occasionally the anterior and posterior horn cells of the cord. Not all these sites are affected in every case, and the cortex is spared.
Psediatricians are uncertain as to when the precise level of hyperbilirubinemia becomes dangerous, but it is known that 20 mg/100 ml is the lower limit at which damage occurs. We feel fairly confident with even a small premature infant, provided he seems healthy and suffers no anoxic episodes. We also know that various environmental factors have a great influence on the liability to kernicterus, and when a premature infant develops hyperbilirubinemia we look for any environmental factor, possibly even iatrogenic, that may be in part responsible for his condition. The tremendous increase in htmolysis that may occur in hxemolytic disease of the newborn is of paramount importance, and it is for this condition that replacement transfusion was evolved. But in addition drugs that increase hxmolysis, including certain vitamin K analogues, will increase the incidence of hyperbilirubinxmia, and drugs that are excreted by conjugation with glucuronide may interfere with the proper conjugation of bilirubin itself; e.g. sulphonamides and chloramphenicol. Moreover, anything which may damage the blood/brain barrier may increase the liability to kernicterus. For instance, kernicterus most often develops in premature infants born after antepartum hamorrhage, or in those with anoxia. This knowledge has come to us painfully through the use of these and other drugs for prophylactic purposes in newborn babies. Treatment: The only means of lowering the plasma bilirubin level is by replacement transfusion, developed first for the overwhelming hyperbilirubinemia and kernicterus of erythroblastosis.
This technique is very successful in holding down the plasma level in hyperbilirubinemia of prematurity and even the smallest infants take the transfusion well and suffer very little disturbance. The prevention of kernicterus in a 'premature unit' entails a routine check on all jaundiced infants, constant vigilance and care and much laboratory work. Clinical jaundice is the early warning signal and as soon as anything more than slight icterus is observed, plasma bilirubins need to be estimated once or twice daily. Replacement transfusion is undertaken when a danger level is approached; two and even three replacements may be necessary.
If it should be doubted that this condition is an inborn error of metabolism, one may refer to two rare, permanent, genetically determined conditions which are based on precisely the same mechanism. In 1907 Gilbert et al. described a family in which several members of more than one generation suffered chronic low-grade jaundice without kernicterus, thought to be hereditary in nature and due to a dominant gene. Many were children of school age. Since then other similar cases have been described in which glucuronyl transferase was absent (Arias & London 1957). More recently Crigler & Najjer (1956) have described a group of related children in Maryland with chronic jaundice, high plasma bilirubin and kernicterus. This group seemed to differ from Gilbert's disease, in that the condition was apparently familial and recessive and much more severe; but it was similar in being due to the same failure of conjugation through lack of the enzyme transferase in the liver cells. No treatment for either condition is at present known.
Galactosemia
Galactosaemia raises clear-cut issues; the treatment is simple and on the whole satisfactory. The monosaccharide galactose is synthesized in the mammary gland of animals, one molecule combining with glucose to form lactose. Lactose is broken down in the intestinal tract into its constituents glucose and galactose which are absorbed. The entry of glucose directly into the Emden-Myerhof pathway of glycolysis by phosphoryla--tion is straightforward. Galactose is similarly phosphorylated, and the resulting 1-phosphate is normally converted to glucose 1-phosphate, this change being effected with the help of the enzyme uridyl phosphor-galactose transferase (see Fig 3) . In galactosemia the enzyme is missing and in consequence galactose and galactose 1-phosphate accumulate in the blood and spill over into the urine. Galactose itself is probably not directly -toxic, but galactose 1-phosphate is a powerful general tissue toxin. The liver cells undergo necrosis of a rather particular type amino-aciduria and a glucosuria superimposed upon the galactosuria, and there Is also in most cases brain damage with convulsions and mental retardation.
The clinical course of a case of galactos'vmia during the first six weeks is illustrated in infection or congenital heart disease was considered first. The urine was examined for pus cells in the laboratory, but there was no comment on the presence of a reducing substance. At three weeks the infant developed twitchings lasting several days. Finally, during the fourth week of life a reducing substance was detected in the urine which was shown to be galactose. Treatment with a synthetic milk completely free of any cow's milk product led to a subsidence of all the symptoms and a steady progress. The course of this child's disease illustrates how easily the diagnosis can be delayed. Though various factors made diagnosis difficult, and though the child is now a cheeerful and happy little boy, earlier treatment might have made this picture ( Fig 5) rather different. His residual hepatic enlargement, his slightly shortened stature and an I.Q. of 95 compared with his brother's 117 might well have been avoided.
There is some argument as to the causation of the twitchings, convulsions and mental impairment which often result from galactosemia. They may well be due to the toxic effects of galactose 1-phosphate itself, but there is often little correlation between these cerebral manifestations and the rest of the disease. Moreover, though the ingestion of milk raises the total blood sugar level it is mainly due to galactose, and low glucose levels are often produced -sometimes as low as 30 and even 20 mg/100 ml. Recurrent hypoglycemia of this degree after the first two or three days of life is well known to give rise to convulsions and to mental retardation.
The particular lessons to be drawn from such a case are that in any infant where there is unexplained failure to thrive or vomitinghowever much the case may appear to be one of simple 'feeding problem' -the possibility of a metabolicerror should be entertained and excluded by suitable biochemical tests. The diagnosis may eventually be reached and dramatic improvement obtained by appropriate treatment, but the penalty for delay may be very serious for the child in terms of irrevocable damage to the liver, kidneys or brain.
Wilson's Disease
Kinnier Wilson's disease, with a very different chronology, has interesting similarities to both the previous conditions. Very little of clinical importance was added to his classical account (1912) with the exception of the description of the pathognomonic Kayser-Fleischer rings in the cornea and the recognition that hepatic damage, though usuallychronic and uncommon, can sometimes be acute and rapidly fatal. It was soon appreciated that copper metabolism was involved and gradually, during the late 1940s and the 1950s, the main features of this defect have been elucidated. Briefly, in Wilson's disease there is a failure of transport of copper in the plasma. The metal is normally absorbed from the alimentary canal and is firmly bound to the protein ceruloplasmin, a globulin present in a concentration of 20-30 mg/100 ml. In Wilson's disease there is a failure in the synthesis of caeruloplasmin, the plasma concentration of which is low or even altogether absent. The disease is, therefore, one of failure of protein synthesis and takes its place as such together with agammaglobulinemia and some of the disturbances of clotting. Copper is consequently no longer tightly bound and is deposited in the tissues. At the same time, for a reason as yet unknown, copper absorption from the gut is increased. Copper appears to be of low-grade toxicity and the following organs are those most easily and severely affected: (I) The liver, leading in time to necrosis of liver cells followed by regeneration and cirrhosis.
(2) The kidney, as revealed by the presence of renal glycosuria and hyperphosphaturia, and an amino-aciduria. This last, though generalized, has certain characteristics which it shares with the amino-aciduria of poisoning by lead and other heavy metals, as well as errors of metabolism.
(3) The brain, leading to gliosis and degeneration of certain nuclear masses which have a distribution reminiscent of kernicterus of hyperbilirubintmia, namely the putamen, the globus pallidus and the caudate nucleus.
During the last few years treatment of Wilson's disease by chelating out the copper has been successful and both BAL and penicillamine have been used. They probably act by possessing available sulph-hydryl (SH) groups. BAL needs to be given intramuscularly every day and is painful, whilst penicillamine is probably more effective and can be given orally with no ill effects.
The rate of progression of this disease is very different from that of kernicterus of hyperbilirubinemia which may kill within days, or galactosemia which may do so within weeks. It seems probable that copper is being accumulated, at least from the time spinach, liver and other coppercontaining foods enter into the diet. Symptoms do not develop until well on in childhood, and Walshe (1962) reported on 20 proven cases with the average age at diagnosis of 14-5 years. Occasionally cases are first recognized in third decade. The important diagnostic features and some of the pitfalls are illustrated by the following case history, published elsewhere in full (Warren & Broughton 1962) , for the details of which I am indebted to Dr C B M Warren and Dr P M G Broughton of Chelmsford.
Case 1 (see Fig 6, upper part) A girl, the eldest of 3 children, was born in 1945 of parents who were cousins. When 7 years old she suffered an attack of subacute liver disease which gave great anxiety, involved hTmolysis and a transfusion as well as a liver biopsy which showed subacute atrophy and nodular hyperplasia. The condition continued intermittently for some eight months and a provisional diagnosis of Weil's disease was made. The child eventually recovered, but was left with hepatic and splenic enlargement.
Early in 1957, when aged 12, she developed slurring speech, salivation, clumsiness, and jerky involuntary movements somewhat like chorea, and she became moody and unstable. The condition became increasingly severe and soon incapacitated her for school life. When first seen she could talk intelligibly and walk with slight difficulty provided she kept calm, but the moment she became excited or hurried she was rendered completely unintelligible and hopelessly unstable on her legs. There were no well-defined abnormal neurological findings, but there were well-marked Kayser-Fleischer rings; the liver was palpable 2 fingerbreadths below the costal margin and the spleen was enlarged. There were slight but significant EEG changes.
Investigation of copper metabolism revealed a greatly reduced plasma cxruloplasmin level and a urinary excretion of copper of 339 ug/24 hours (normal <50 ,ug/24 h).
Treatment: (1) A low-copper diet without cocoa, mushrooms, spinach, liver or shellfish. (2) Potassium sulphide to reduce the copper absorption from the gut.
(3) Penicillamine orally 0 3 g t.d.s.
Her copper excretion rose steadily to some 2,000 jig daily. Within a few weeks clinical improvement began, and after three months she was discharged home on the same dose of 0-9 g penicillamine a day. In May 1958, eight months after the start of treatment, she was was then discontinued. It later transpired that, owing to a misunderstanding, she had, from the time of her discharge from hospital, been receiving only half the intended daily dose of 0 9 g of penicillamine. Within a month or two her symptoms returned and became increasingly severe. The daily excretion of copper fell in response to penicillamine (not marked on Fig 6) , and for a time the response to treatment seemed to be fading. It was at this time considered possible that the daily excretion of copper was related to the total copper pool and might continue low in spite of the return of symptoms. The dose of penicillamine was increased to 0 9 g and later to 1-2 g daily. This produced an improvement not only in the clearance of copper but also in the clinical symptoms, with a second remission more complete than the first. The changes in the EEG improved. The changes in her condition are reflected in her handwriting (Fig 7) .
She was able to return to her school for the second time, and is now working normally, though with difficulty.
The second child, a brother, is clinically and biochemically normal. Her younger brother is Case 2. .anges in handwriting tefore and during treatment when he was 6 years of age. He was neurologically and psychologically normal, but had a hepatic enlargement and a palpable spleen. Daily urinary excretion of copper 468 pg (normal <50 pg), substantially higher than his sister's. Oral penicillamine given for a few days increased the copper excretion to 1,770 ,g/24 hours. Owing to the cost of treatment and his apparent well-being, he was left untreated until two years later when a change began to appear in the EEG, and he lost his phlegmatic disposition. A liver biopsy showed fibrosis and nodular hyperplasia. He was placed on similar treatment to his sister, namely low-copper diet, potassium sulphide, and oral penicillamine 0 9 g daily.
There was a prompt response in his biochemical findings and a return to his normal placid disposition. Both these children are now living normal active and intelligent lives.
Several lessons may be learned from this story.
(1) The biochemical findings are present for many years before they produce symptoms. However, with gene frequency of about 1: 2,000, and therefore case incidence of 1: 4,000,000, a universal screening test is scarcely practical. Nevertheless any curious attack of chronic or recurrent hepatitis, with hemolysis and anemia, or even unexplained hepatic and splenic enlargement, particularly when occurring in more than one member of the family, should prompt one to investigate the copper metabolism. (2) The impor-tance of careful follow-up and of checking all procedures with the parents, lest errors creep in which might prejudice successful treatment.
(3) There are interesting similarities between this condition and the two others described earlier. All three metabolic disturbances result in the accumulation of a toxic metabolite which severely affects neurones, though at very different rates. Bilirubin is primarily a neurotoxin, perhaps because of its fat-soluble nature, but galactosaemia and Wilson's disease give rise to a general tissue toxin which in turn leads to liver and renal damage, either or both of which may give the physician an all-important clue before it is too late.
(4) Constant alertness on the part of the piediatrician, as well as the general physician and neurologist, may prevent permanent damage in these and other metabolic disturbances. These three case histories demonstrate, however, that minor delays in diagnosis or errors and misunderstanding in treatment can easily lead to permanent tissue damage.
Dr L I Woolf' (Radcliffe Infirmary, Oxford)
Recent Work on Phenylketonuria and Maple Syrup Urine Disease (Leucinosis)
In both phenylketonuria and maple syrup urine disease an inborn error in the metabolism of amino acids is associated with profound mental retardation and neurological abnormalities. The view was once held that this association was a coincidence, and that the gene responsible for phenylketonuria caused the mental deficiency, possibly by changes in the foetal brain, independently of its effect on metabolism, which was thought to be little more than a convenient curiosity. It is now recognized that the mental and neurological signs of Ithese two diseases are due to an intoxication by one or more of the substances present in the blood in abnormal concentrations and thus stem directly from the metabolic errors. The details of the mechanism by which the brain is affected still have to be worked out and 'Member of External Staff of the Medical Research Council. the data which are accumulating have to be correlated with the known features of the disease.
The first stage in the metabolism of phenylalanine is normally hydroxylation to tyrosine, catalysed by the enzyme phenylalanine hydroxylase in the liver. Production of this enzyme is under the control of a single allelomorphic pair of genes; if both genes are absent or have undergone mutation so that they produce no active enzyme, the individual develops phenylketonuria. Phenylalanine, since its normal path is blocked, accumulates in the body fluids and tissues, frequently reaching a concentration in the blood of 40 mg/100 ml or more, as compared with a normal concentration of about 1 mg/100 ml. As a consequence of this very high concentration of phenylalanine in the tissues, it undergoes a series of reactions, which normally play only a minor part in its metabolism, to produce phenylpyruvic acid, phenyllactic acid, phenylacetylglutamine and o-hydroxyphenylacetic acid. The same substances are produced by a normal individual if he is given a large dose of phenylalanine or phenylpyruvic acid.
In maple syrup urine disease three amino acids, leucine, isoleucine and valine, accumulate. Three groups of workers simultaneously and independently suggested that this disease was an inborn error of the second stage in the metabolism of these amino acids (Menkes 1959 , Mackenzie & Woolf 1959 , Dancis et al. 1959 . Leucine, isoleucine and valine are normally metabolized first by transamination to the corresponding a-ketoacids, then these react further by oxidative decarboxylation to produce three branched-chain fatty acids. The enzyme or enzymes for the second reaction are absent or inactive in maple syrup urine disease and, in consequence, the three branched-chain oc-keto-acids accumulate, are partly excreted in the urine and partly reconverted to leucine, isoleucine and valine, since the transamination reaction is reversible. The a-keto-acids also react in other ways, producing the odoriferous substances that, excreted in the urine, give the condition its name of maple syrup urine disease. Salt (1961, personal communication) has suggested that, instead of this clumsy and misleading term, the disease be called 'leucinosis'. This seems apt, stressing the similarities to tyrosinosis, oxalosis and cystinosis, and 'leucinosis' will be used throughout the rest of this paper.
The clinical features of phenylketonuria are well known; most patients are grossly retarded mentally with an intelligence quotient under 30 in about 65 % of patients and between 30 and 60 in 33% (Knox 1960 ). There appears to be a small separate group of phenylketonuric individuals with normal intelligence (Woolf et al. 1961) .
About 200% of phenylketonurics have epileptic seizures, usually during childhood, and 95 % have some abnormality of the EEG (Fois et al. 1955) .
Leucinosis is characterized by progressive cerebral degeneration; the affected infant ceases to suck a few days after birth. In many cases the infant goes rapidly downhill, with attacks of rigidity, opisthotonos and finally apncea, dying within a few weeks of birth. In some the disease runs a slower course and death occurs only after several months, though usually during the first two years of life; these cases show marked intellectual retardation, a gross abnormality of the EEG and sometimes grand mal (Mackenzie & Woolf 1959; Silberman et al. 1961 ). There is one recorded case of a child with leucinosis who was alive and physically well at 7 years of age, though mentally retarded (Silberman et al. 1961) .
Eleven years ago it was suggested that the mental deficiency of phenylketonuria was due to an intoxication of the brain by phenylalanine or its abnormal metabolites and that a diet low in phenylalanine might be beneficial (Woolf & Vulliamy 1951) . This prediction has been amply confirmed; if a diet low in phenylalanine is given from early infancy, the child develops normal intelligence and shows no neurological abnormalities; if started later in childhood the low-phenylalanine diet frequently causes an improvement in intelligence and behaviour and a change in the EEG towards the normal, with fewer fits (for review see Knox 1960 , Woolf 1962 .
Leucinosis so closely resembles phenylketonuria that it seems reasonable to attempt dietary treatment along similar lines to those that have proved so successful for phenylketonuria. A diet low in leucine, isoleucine and valine has been fed to one or two children who since are doing reasonably well. Such a diet is even more difficult to prepare than in the case of phenylketonuria, but Dent & Westall (1961) , by an ingenious use of ion-exchange resins, succeeded in removing the leucines and valine from a protein hydrolysate.
The mechanism of the intoxication by phenylalanine or its abnormal metabolites has been the subject of much speculation and experiment, particularly on the inhibition of enzymes which produce synaptic transmitters. Dopa-decarboxylase, necessary for the production of noradrenaline, is inhibited by phenylpyruvic acid. Davison & Sandler (1858) found that 5-hydroxytryptophan decarboxylase, which produces 5-hydroxytryptamine, was inhibited by several of the abnormal metabolites present in phenylketonuria. Glutamic acid decarboxylase, which produces y-aminobutyric acid, is inhibited by phenylpyruvic acid and also by the o-keto-acids corresponding to leucine, isoleucine and valine.
In phenylketonuria the results of histological examination of the brain have not been wholly consistent; in some cases virtually no abnormality was found, but in about a third deficient myelination was noted (Crome & Pare 1960) . Recently the white matter of some of these brains has been examined chemically. A marked loss of total solids and a lower content of cerebrosides and cholesterol than in the white matter of the normal brain were the chief findings (Crome et al. 1962 ). This is strong evidence of failure to myelinate or of loss of myelin, and is in accordance with the histological evidence of a reduction in the number of myelinated fibres per unit of volume; however, chemical examination revealed deficient myelination even in cases where no abnormality was detected histologically. Esterified cholesterol was virtually absent from all but one of the phenylketonuric brains; this fitted in well with the lack of histological evidence of active demyelination except in this one patient, who showed the changes characteristic of Schilder's disease (Crome 1962 , Crome et al. 1962 .
Post-mortem findings in leucinosis have been fairly consistent, with cedema of the brain and marked deficiency of myelination as the main features. In one case, dying at 20 months, this amounted to status spongiosus and an almost complete absence of myelin (Crome et al. 1961 ). In four other cases the findings were similar, though the degree of dysmyelination varied from case to case (Silberman et al. 1961 ). The axons were normal in number and morphology and there was no evidence of myelin breakdown. In no case were any malformations of the brain detected such as occur in intra-uterine life, supporting the view that the changes in leucinosis occur after birth and are the result of the metabolic error. The brain of a child who died of leucinosis at the age of 17 days, obtained through the kindness of Professor D V Hubble and Mr H B Salt, was analysed chemically. The water content was 89 Y., cerebrosides were almost completely absent (0'37 % of dry weight) and cholesterol formed 6'9°% of the dry weight. There was very little esterified cholesterol. The cerebroside content was only one-tenth of the normal, indicating a gross deficiency of myelination.
Any theory linking the error in metabolism, in these two diseases, with the mental and neurological features must take into account the effect on enzymes synthesizing synaptic transmitters, the deficient myelination, the demyelination occurring in some cases, and the reduced number of fibres in the white matter in phenylketonuria but not in leucinosis.
These two diseases are not rare curiosities; from 0-5 to 1 % of patients in mental deficiency colonies are phenylketonurics and it is estimated that there are between 1,600 and 2,000 in Great Britain. In some parts of the British Isles the prevalence of phenylketonuria may be as high as 1 in 4,000. There are no comparable figures for leucinosis, but, like phenylketonuria, the disease is very probably inherited recessively and the absence of consanguinity in the parents of all cases reported so far suggests that the gene responsible is not very rare. Leucinosis may be as common as phenylketonuria but, because many patients die during the first few weeks of life when perinatal mortality is at its height, the diagnosis is not made.
Meeting February 1 1962 at the Maida Vale Hospital, London
The following cases were shown: 
